Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes

A.M. Pietroboni, T. Carandini, Annalisa Colombi, M. Mercurio, L. Ghezzi, G. Giulietti, M. Scarioni, A. Arighi, C. Fenoglio, M.A. De Riz, G.G. Fumagalli, P. Basilico, M. Serpente, M. Bozzali, E. Scarpini, D. Galimberti, G. Marotta

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)280-287
Number of pages8
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume46
Issue number2
DOIs
Publication statusPublished - 2019

Keywords

  • Amyloid
  • Amyloid tracer
  • Florbetapir
  • Multiple sclerosis
  • PET
  • White matter
  • amyloid beta protein[1-42]
  • florbetapir f 18
  • amyloid beta protein
  • adult
  • anterior cingulate
  • Article
  • brain size
  • cerebrospinal fluid
  • clinical article
  • clinical assessment
  • comparative study
  • controlled study
  • damaged white matter
  • disease activity
  • disease duration
  • disease exacerbation
  • Expanded Disability Status Scale
  • female
  • human
  • isoelectric focusing
  • low drug dose
  • lumbar puncture
  • male
  • mean standardized uptake value
  • middle aged
  • multiple sclerosis
  • neurologic examination
  • neuropsychological test
  • normal appearing white matter
  • nuclear magnetic resonance imaging
  • oncological parameters
  • paced auditory serial addition test
  • positron emission tomography
  • posterior cingulate
  • precuneus
  • superior parietal lobule
  • symbol digit modalities test
  • temporal lobe
  • white matter
  • young adult
  • diagnostic imaging
  • metabolism
  • pathology
  • reference value
  • standards
  • Adult
  • Amyloid beta-Peptides
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Sclerosis
  • Positron-Emission Tomography
  • Reference Values
  • White Matter
  • Young Adult

Cite this